Oxymatrine injection
Function and Efficacy
Pharmacological experiments have shown that it has a significant effect on increasing the number of peripheral blood leukocytes in normal rabbits. The peak of the leukocyte count occurs on the fourth day after the first administration, which is 72% higher than before the administration, which is better than the leukocyte-raising drug shark liver alcohol. It has a significant effect on the leukopenia of rabbits caused by cobalt 60-gamma rays and deep X-ray irradiation. It also has a preventive effect on leukopenia when administered two days before irradiation. It can also prevent leukopenia in mice caused by mitomycin C. It has a synergistic inhibitory effect on the solid type of Ehrlich carcinoma when used in combination with cyclophosphamide, and the toxicity of leukopenia caused by cyclophosphamide is significantly reduced.
Ingredients
The main ingredient of this product is matrine, also known as oxymatrine.
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| AmmothamnineIngredients |
It has a significant effect on increasing the number of peripheral blood leukocytes in normal rabbits. The peak value of leukocyte count occurs on the 4th day after the first administration, which is 72% higher than that before administration, which is better than the leukocyte-increasing drug shark liver alcohol. It has a significant effect on increasing leukocytes in rabbits induced by cobalt 60-gamma ray and deep X-ray irradiation. It also has a preventive effect on leukocyte decrease when administered two days before irradiation. It can prevent leukopenia in mice caused by mitomycin C. It has a synergistic inhibitory effect on the solid type of Ehrlich carcinoma when used in combination with cyclophosphamide, and at the same time significantly reduces the toxicity of leukocyte decrease caused by cyclophosphamide. More |
16837-52-8 | 11 |
Appearance
This product is an almost colorless or yellow clear liquid.
Indication
Used for the treatment of chronic hepatitis B and low white blood cell count caused by tumor radiotherapy and chemotherapy, as well as leukocytopenia caused by other reasons.
Usage and Dosage
Intramuscular injection. For the treatment of chronic hepatitis B, once a day, 400-600 mg each time. For increasing white blood cell count, twice a day, 200 mg each time.
Adverse Reactions
1. Common symptoms include dizziness, nausea, vomiting, bitter taste in the mouth, upper abdominal discomfort or pain, diarrhea, etc. 2. Occasionally, rashes, chest tightness, and fever may occur, which generally resolve on their own. 3. Some patients may experience redness at the injection site. Local pain may also occur, which can be alleviated by changing to deep intramuscular injection.
Precautions
1. Patients with severe blood, heart, liver, kidney and endocrine diseases are prohibited from using this product. 2. Pregnant women are prohibited from using this product. 3. Patients who are allergic to this product or have a history of anaphylactic shock are prohibited from using this product. 4. Patients with severe renal insufficiency are not recommended to use this product.
Special Population Medication
Precautions for children: There is no experience of using the drug for children. Precautions for pregnancy and lactation: Pregnant women are prohibited from using this drug. Precautions for the elderly: Reduce the dosage or follow the doctor's advice.
Drug Interactions
Not yet clear.
Storage
Keep away from light, tightly closed, in a cool place.
Packaging Specification
2ml:0.2g (based on oxymatrine)
Validity Period
24 months
Manufacturer
Jilin PROVINCE Tonghua Zhenguo Pharmaceutical Co., Ltd.
-
Founded in:
1995-09-13 -
Address:
Wanwanchuan Botanical Garden, Tonghua County, Jilin Province -
Tax NO.:
91220505605220911A -
Registered Funds:
133.77 million yuan -
Website:
-
Email: